September 29, 2026
Company Name: AnGes Inc.
Presentative: Ei Yamada, President & CEO

Notice of Completion of Patient Enrollment in the Phase 2a Clinical Trial of Co-Developed Tie2 Receptor Agonist AV-001

We are pleased to announce that patient enrollment has been completed in the Phase 2a clinical trial of the Tie2 receptor agonist AV-001 (pegevongitide : "AV-001"), which we are co-developing with Vasomune Therapeutics Inc. (Canada; CEO: Dr. Brian E. Jahns; "Vasomune").

AV-001 is currently being evaluated in a clinical trial in the United States for the treatment of Acute Respiratory Distress Syndrome (ARDS), including ARDS associated with viral and bacterial pneumonia. While the originally planned patient enrollment had been completed by the end of 2025, additional enrollment had continued to replace patient dropouts. We are pleased to report that this additional enrollment has now also been completed.

Following the completion of enrollment, we will proceed with data analysis and other necessary activities with the aim of reporting topline results from the trial as soon as possible.

As previously announced in May 2024 in the press release entitled "*Co-Developed Tie2 Receptor Agonist (AV-001) Receives Fast Track Designation from the U.S. FDA*," AV-001 has been granted Fast Track designation by FDA. The Fast Track program is designed to facilitate and expedite the development and review of drug candidates intended to treat serious conditions and address unmet medical needs.

The completion of patient enrollment is not expected to have any impact on the Company's consolidated financial results for the fiscal year ending December 31, 2026.
Should any matters requiring disclosure arise in the future, we will promptly make an announcement.

For further details, please refer to the attached press release.

(Note)This document has been translated from the Japanese original for reference purposes only.
In the event of any discrepancy between this translation and the Japanese original, the original shall prevail.

Vasomune Therapeutics Completes Enrollment of Phase 2a Study of Pegevongitide (AV-001) in Patients Hospitalized with Pneumonia/ARDS

Enrollment milestone advances the FDA Fast Track-designated program toward data review and analysis

Vasomune Therapeutics Inc. (“Vasomune”), a clinical-stage biopharmaceutical company developing medicines that target endotheliopathy and vascular leak, today announced the completion of patient enrollment in AV001-004 (NCT05123755), its randomized, double-blind, placebo-controlled Phase 2a clinical study evaluating Pegevongitide (AV-001) in patients hospitalized with pneumonia requiring supplemental oxygen.

Pegevongitide has received Fast Track designation from the U.S. Food and Drug Administration for the prevention and treatment of moderate-to-severe acute respiratory distress syndrome associated with respiratory infection. The designation is intended to facilitate the development and review of therapies for serious conditions with unmet medical needs.

With enrollment concluded, Vasomune and its clinical researchers will now focus on data quality assurance and quality control, clinical-data review and cleaning, site closeout activities and preparation for database lock.

“Completing enrollment is an important milestone for Vasomune and for the clinical development of Pegevongitide,” said Dr. Brian E. Jahns, Chief Executive Officer of Vasomune Therapeutics. “Pneumonia can destabilize the pulmonary vasculature, resulting in pulmonary edema and impaired oxygen exchange. Pegevongitide is designed to correct this vascular response by activating Tie2 and reinforcing the endothelial barrier, regardless of whether the underlying infection is viral or bacterial.”

“We are grateful to the patients and families who participated in this study and to the investigators, clinical research teams and hospital staff who made its execution possible,” Mr. Shahid Ahmad, Vice-President of Operations, stated.

“Completion of enrollment represents another important step in the clinical evaluation of Pegevongitide,” said Dr. Ei Yamada, President and Chief Executive Officer of AnGes Inc. “We appreciate the commitment of the patients, investigators and clinical teams participating in AV001-004. AnGes remains committed to working with Vasomune to evaluate the potential of Pegevongitide as a new therapeutic approach for patients hospitalized with serious respiratory infections.”

AV001-004 is evaluating the safety, tolerability and exploratory efficacy of multiple intravenous administrations of Pegevongitide compared with placebo, each administered together with standard of care. The study enrolled patients hospitalized with presumed or documented viral or bacterial pneumonia requiring supplemental oxygen.

Pegevongitide is a first-in-class, fully synthetic PEGylated peptide designed to activate Tie2, a receptor that plays an important role in maintaining endothelial stability and vascular-barrier integrity. By reinforcing the vascular barrier, Pegevongitide is intended to reduce the leakage of fluid and proteins from blood vessels into surrounding tissues.

Vasomune is indebted to the United States Department of Defense Congressionally Directed Medical Research Programs award number W81XWH-21-1-0834 for support of study AV001-004.

About Vasomune Therapeutics, Inc.

Vasomune Therapeutics, Inc., is a private clinical-stage biopharmaceutical company developing the next generation of medicines to boost the body’s ability to defend against endotheliopathy and vascular leak. Pegevongitide (AV-001), discovered and researched at Sunnybrook Research Institute at Sunnybrook Hospital in Toronto, is a novel investigational medicine being developed by Vasomune Therapeutics under a co-development agreement with AnGes, Inc. [TYO: 4563] to target endotheliopathy and vascular leak. Pegevongitide is a first-in-class, PEGylated peptide that activates the Tie2 receptor, a transmembrane protein highly expressed on the surface of endothelial cells in the vasculature, thereby blocking vascular leak. Endotheliopathy, or the breakdown of the endothelial barrier that lines blood vessels, allows fluid and proteins to quickly escape circulation and leak into surrounding tissues, often causing edema and end-organ failure. Vascular leak is a common and deadly underlying pathology seen in a broad range of disease states including bacterial and viral pneumonia, acute respiratory distress syndrome (ARDS), hemorrhagic shock, trauma and shock following severe burns. Vasomune's corporate headquarters and laboratories are located in Toronto, Canada, with U.S. offices in Raleigh, NC. For more information, please visit https://vasomune.com/.

About AnGes, Inc.

AnGes, Inc., a biopharmaceutical company founded in December 1999, focuses on the development of gene-based medicines. The company's flagship development product and genetic drug, HGF gene therapy products, received Breakthrough Therapy designation from the FDA in 2024. AnGes is currently working on the development of a Tie2 tyrosine kinase receptor agonist for the treatment of vascular leak and an NF-κB decoy oligonucleotide for chronic discogenic lumbar back pain. Furthermore, AnGes acquired EmendoBio in December 2020 to expand its capabilities in genome-editing technologies. For more information, visit https://www.anges.co.jp/en/.